Highlights Apellis Pharmaceuticals, Inc.

Equities

APLS

US03753U1060

Real-time Estimate Cboe BZX Other stock markets 10:52:26 2024-06-07 am EDT			5-day change	1st Jan Change
41.63 ^USD	+1.41%		+5.59%	-30.76%

May. 31	Piper Sandler Starts Apellis Pharmaceuticals With Neutral Rating, $46 Price Target	MT
May. 24	Apellis Pharmaceuticals, Sobi Say Pegcetacoplan Reduces Post-Transplant Kidney Diseases	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Apellis Pharmaceuticals, Sobi Say Pegcetacoplan Reduces Post-Transplant Kidney Diseases	May. 24	MT
Apellis Pharmaceuticals, Inc. Announces Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress	May. 24	CI
Apellis Pharmaceuticals Enters Into Senior Secured Credit Facility With Sixth Street	May. 14	MT
Apellis Pharmaceuticals Q1 Net Loss Narrows, Revenue Rises	May. 07	MT
Earnings Flash (APLS) APELLIS PHARMACEUTICALS Reports Q1 Revenue $172.3M	May. 07	MT
Apellis Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Apellis Pharmaceuticals Says EMA Moves Pegcetacoplan Application to Last Phase of Initial Assessment	Apr. 26	MT
Apellis Announces Pegcetacoplan MAA Review Reset to Initial Assessment by European Medicines Agency	Apr. 26	CI
Apellis Pharmaceuticals' Q4 Net Loss Narrows, Revenue Increases	Feb. 27	MT
Apellis Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 27	CI
Earnings Flash (APLS) APELLIS PHARMACEUTICALS Reports Q4 Revenue $146.4M	Feb. 27	MT
Apellis Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
North American Morning Briefing : Rate Doubts Keep -2-	Feb. 06	DJ
Apellis Pharmaceuticals, Inc. Announces Negative CHMP Opinion for Pegcetacoplan for Ga in the European Union and Plans to Seek Re-Examination of Application	Jan. 26	CI
Apellis says EU regulator panel may not back its eye disease drug	Dec. 14	RE
Apellis Pharmaceuticals, Inc. Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European Union	Dec. 14	CI
Apellis Pharmaceuticals, Inc. and Sobi Presents Post Hoc Data that Reinforce the Long-Term Efficacy and Safety of EMPAVELI	Dec. 11	CI
Apellis Pharmaceuticals Shares Rise on Updates for US Prescribing Information for Syfovre	Dec. 01	MT
Apellis Pharmaceuticals Q3 Loss Narrows, Revenue Rises	Nov. 01	MT
Earnings Flash (APLS) APELLIS PHARMACEUTICALS Reports Q3 Revenue $110.4M	Nov. 01	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Apellis Pharmaceuticals, Inc.

Equities

APLS

US03753U1060

Highlights

Filters